Grupo para la caracterización molecular de las neoplasias hematológicas
Universidade da Coruña
La Coruña, EspañaPublicaciones en colaboración con investigadores/as de Universidade da Coruña (10)
2022
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers
Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8
-
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Leukemia, Vol. 35, Núm. 6, pp. 1571-1585
-
Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
Therapeutic Advances in Gastroenterology, Vol. 14
2020
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
2018
-
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment
Hematological Oncology, Vol. 36, Núm. 5, pp. 765-772
-
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: A long-term follow-up analysis from the Spanish GELTAMO registry
Bone Marrow Transplantation
2017
-
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure
Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 10, pp. 1631-1640
-
Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma
Cancer Medicine, Vol. 6, Núm. 12, pp. 2766-2774